Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Transplant Proc ; 42(5): 1643-7, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20620492

ABSTRACT

BACKGROUND AND PURPOSE: The influence of African-American ethnicity on outcomes of kidney transplant recipients subjected to early steroid withdrawal remains controversial. Recent studies that suggest no higher risk among African Americans may be biased by recruitment of relatively small number of African Americans or by patient selection. We compared outcomes of African Americans to non-African Americans in a center in which early steroid withdrawal has become the standard of practice. METHODS: This was a single-center prospective study of 133 consecutive patients receiving primary kidney transplants between January 2006 and December 2008, followed for >or=3 months, and managed with a similar immunosuppression regimen that included induction antibody therapy, tacrolimus, mycophenolate mofetil, and withdrawal of steroids on postoperative day 5. Acute rejection and other outcomes were compared in African-American patients (n = 55) and compared with those of non-African-American patients (n = 78). RESULTS: During the first 12 months after early steroid withdrawal, African-American patients experienced a significantly higher cumulative incidence of acute rejection than non-African Americans (23.6% vs 7.7%; P = .020). Using multivariate logistic regression, ethnicity (odds ratio 3.33; P = .047) and HLA mismatch (odds ratio 1.44; P = .041) were significantly correlated with acute rejection independent of recipient age, gender, historical peak panel reactive antibody level (PRA) or PRA at time of transplant, time on dialysis, or donor source. CONCLUSIONS: African Americans are at increased risk of acute rejection after early steroid withdrawal, particularly when they receive kidneys from poorly matched donors.


Subject(s)
Adrenal Cortex Hormones/therapeutic use , Black or African American/statistics & numerical data , Ethnicity/statistics & numerical data , Graft Rejection/epidemiology , Kidney Transplantation/physiology , Adult , Aged , Drug Administration Schedule , Drug Therapy, Combination , HLA Antigens/immunology , Histocompatibility Testing , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/immunology , Living Donors/statistics & numerical data , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Prednisone/administration & dosage , Prednisone/therapeutic use , Substance Withdrawal Syndrome/epidemiology
3.
Am J Transplant ; 10(2): 310-4, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20055793

ABSTRACT

Proteinuria is an increasingly recognized effect of sirolimus (SRL) therapy in kidney transplant recipients. Predictors of proteinuria after conversion to SRL are not well described, and in particular the risk in African-American (AA) kidney recipients is unknown. We sought to analyze risk factors for proteinuria with SRL therapy in a cohort of 39 patients (44% AA) converted from tacrolimus to SRL at a mean time of 4 months posttransplantation. Patients were maintained on therapy with mycophenolate mofetil while most patients underwent early steroid withdrawal. Urinary protein to creatinine ratio (Up/cr) at a mean of 14 months postconversion increased to > or =500 mg/g in 65% of AAs versus 14% of non-AAs (p = 0.001). Mean arterial blood pressure at the time of conversion and pretransplant proteinuric kidney disease were also predictors of proteinuria after SRL conversion. In conclusion, AAs appear to be at high risk for proteinuria and should be monitored closely after conversion to SRL in calcineurin inhibitor sparing protocols.


Subject(s)
Immunosuppressive Agents/therapeutic use , Kidney Diseases/physiopathology , Kidney/physiopathology , Proteinuria/chemically induced , Adult , Female , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/pharmacology , Kidney Diseases/chemically induced , Kidney Diseases/drug therapy , Kidney Function Tests , Male , Middle Aged , Mycophenolic Acid/analogs & derivatives , Proteinuria/drug therapy , Proteinuria/physiopathology , Risk Factors , Sirolimus/adverse effects , Sirolimus/pharmacology , Sirolimus/therapeutic use , Steroids/pharmacology , Steroids/therapeutic use , Tacrolimus/pharmacology , Tacrolimus/therapeutic use
4.
Curr Mol Med ; 5(5): 497-507, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16101479

ABSTRACT

Chronic kidney disease (CKD) is common, progressive and expensive to manage. Although modifiable risk factors can be treated and outcomes improved, CKD remains a chronic disease with excessive morbidity and mortality. The completion of the human genome sequence and the advent of methodologies to define gene function provide new opportunities to manage and treat patients with CKD and other chronic diseases. Despite the lack of clear correspondence between genotype and phenotype and an obvious Mendelian inheritance pattern, CKD susceptibility has a genetic basis. In this review, we focus on recent studies of familial focal segmental glomerulosclerosis and the discoveries that have resulted from both genetic and genomic approaches used to understand its pathogenesis. Key slit diaphragm proteins were discovered using linkage analyses of these rare causes of glomerulosclerosis and subsequent work has characterized slit diaphragm function in health and disease. Podocyte dysfunction is now recognized as a key contributor to the functional and histologic derangements that characterize glomerular dysfunction in many common causes of CKD. In aggregate, these studies provide a paradigm for approaches to better define mechanisms of CKD and to identify novel therapeutic targets.


Subject(s)
Genetic Linkage , Genetic Predisposition to Disease , Genome, Human , Glomerulonephritis/genetics , Quantitative Trait Loci/genetics , Animals , Chronic Disease , Glomerulonephritis/metabolism , Humans
5.
J Neurosci Nurs ; 33(6): 326-37, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11776715

ABSTRACT

Back pain is epidemic, and dozens of books inform the public about this disorder. The increase in "self-help" medical books has not been accompanied by objective critiques of this important literature. We conducted an objective, quantified evaluation of the comprehensiveness and quality of these books. A Books in Print search resulted in 38 books on back pain, of which 27 were found and purchased. Topics covered, organization, and emphasis were coded according to scales with excellent interrater reliability. Alternative and conventional treatments were emphasized in most books, but epidemiology, natural history, and risk factors were substantially de-emphasized, covering less than 3% of the text. This objective and validated evaluation of the consumer literature provides a format for researching patient education in other health areas.


Subject(s)
Back Pain/therapy , Community Participation , Complementary Therapies , Patient Education as Topic , Self Care , Back Pain/etiology , Back Pain/physiopathology , Humans , Publishing , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...